Visual Outcomes of a New Hydrophobic Trifocal Intraocular Lens in Cataract Treatment: A Prospective Clinical Study.

To report the visual outcomes following bilateral implantation of a new trifocal intraocular lens (IOL) in patients with age-related cataracts. This prospective, noncomparative, multicenter study assessed 126 patients undergoing cataract extraction followed by AT ELANA 841P IOL implantation. At 4-6 months postoperatively, refractive error and predictability, monocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance-corrected intermediate visual acuity (DCIVA), uncorrected near visual acuity (UNVA), distance-corrected near visual acuity (DCNVA), and binocular contrast sensitivity were measured. The binocular defocus curve was evaluated at 3 months postoperatively. Postoperatively, most of the eyes (84.9%) were within ±0.5 D of spherical equivalent (SE) refraction and almost all eyes (98.9%) within ±1.0 D, with a mean SE value of -0.11 ± 0.37 D. Mean monocular CDVA was -0.06 ± 0.08 logMAR and UDVA was -0.01 ± 0.10 logMAR. Mean monocular uncorrected (UIVA and UNVA) and distance-corrected visual acuities (DCIVA and DCNVA) were 0.1 logMAR or better at intermediate (80 cm) and near (40 cm) distances. In the mean defocus curve, a continuous range of 0.1 logMAR or better vision from distance to near was observed. Percentages of eyes achieving CDVA, DCIVA, and DCNVA of 0.1 logMAR or better were 97.2%, 59.1% and 59.1%, respectively. Uncorrected visual acuity of 0.1 logMAR or better was achieved in 88.9% of the eyes at far, 57.1% at intermediate, and 44.4% at near distances. Contrast sensitivity was in the normal range of a phakic population at all spatial frequencies in all light conditions tested, photopic with glare and mesopic with and without glare. Implantation of the new AT ELANA 841P IOL following cataract extraction is safe and effective. Visual acuities at all distances, refractive outcomes, and contrast sensitivity were favorable at 4-6 months postoperatively, providing patients with satisfactory far, intermediate, and near vision. ClinicalTrials.gov identifier: NCT06247683.